Shots:

• Genentech to receive a $30M one-time option fee on Abs targeting CD20 & is eligible to receive the development expenses of the product incurred during 2021 while Biogen is eligible to receive royalties on sales outside the US & will share the profits and losses of mosunetuzumab in the US
• Biogen gets the joint decision-making rights for the development and commercialization of mosunetuzumab and Genentech will be responsible to lead the strategy and implementation of the program
• Genentech is planning to complete a BLA submission for approval of mosunetuzumab in the (GO29781) study for patients with R/R FL. If approved, the therapy will be the 1st CD20xCD3 T-cell engaging bispecific Ab in NHL

Ref: Biogen | Image: Biogen